Retinal and choroidal microangiopathies: Therapeutic opportunities

Microvascular Research

Volumn 74, Issue 2-3, 2007, Pages 131-144

  Afzal, A ^a   Shaw, L C ^a   Ljubimov, A V ^b   Boulton, M E ^c   Segal, M S ^d   Grant, M B ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

secretase; Age related macular degeneration; Angiogenesis; Antiangiogenic; CD133; CD14; CD34; Choroidal neovascularization; CXCR4; Delta like ligand 4; Endothelial progenitor cell; Hematopoietic stem cell; Hypoxia; IGF 1; IGF 1R; IGFBP 3; Ischemia; PEDF; Proliferative retinopathy; Protein kinase CK2; Retinopathy of prematurity; SDF 1; Somatostatin analogs; Therapies; Vascularization; VEGF; VEGFR 1; VEGFR 2

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; ACETYLCHOLINE; ANTITHROMBIN; CONNECTIVE TISSUE GROWTH FACTOR; CYTOKINE; EMODIN; ERYTHROPOIETIN; ESTROGEN; FIBULIN; GAMMA SECRETASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN GROWTH FACTOR 1 RECEPTOR ANTAGONIST; INTEGRIN; INTERSTITIAL COLLAGENASE; OCREOTIDE LAR; OCTREOTIDE; OMEGA 3 FATTY ACID; PIGMENT EPITHELIUM DERIVED FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE INHIBITOR; PX 478; SEMAXANIB; SOMATOMEDIN; SOMATOSTATIN DERIVATIVE; STROMAL CELL DERIVED FACTOR 1; THROMBOCYTE FACTOR 4; THROMBOSPONDIN; TOPOTECAN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BONE MARROW; CARDIOVASCULAR RISK; CELL FUNCTION; CHOROID; CLINICAL TRIAL; DRUG MECHANISM; ENDOTHELIUM CELL; HEMATOPOIETIC STEM CELL; HUMAN; HYPOXIA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA NEOVASCULARIZATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; WOUND HEALING;

ANGIOGENESIS INHIBITORS; ANIMALS; CHOROID; CHOROIDAL NEOVASCULARIZATION; EYE DISEASES; HUMANS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; RETINAL NEOVASCULARIZATION; RETINAL VESSELS;

EID: 35748946948     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2007.04.011     Document Type: Review

References (171)

1. Abraham-Marin M.L., Cortes-Luna C.F., Alvarez-Rivera G., Hernandez-Rojas M., Quiroz-Mercado H., and Morales-Canton V. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration: a pilot study. Graefe's Arch. Clin. Exp. Ophthalmol. (2006)
2. Adamis A.P., Altaweel M., Bressler N.M., Cunningham Jr. E.T., Davis M.D., Goldbaum M., Gonzales C., Guyer D.R., Barrett K., and Patel M. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113 (2006) 23-28
3. Adamis A.P., Miller J.W., Bernal M.T., Folkman D.A., Yeo J., and Yeo T.K. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118 (1994) 445-450
4. Ahmad K.A., Wang G., Slaton J., Unger G., and Ahmed K. Targeting CK2 for cancer therapy. Anti-cancer Drugs 16 (2005) 1037-1043
5. Aicher A., Brenner W., Zuhayra M., Badorff C., Massoudi S., Assmus B., Eckey T., Henze E., Zeiher A.M., and Dimmeler S. Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation 107 (2003) 2134-2139
6. Aicher A., Heeschen C., and Dimmeler S. The role of NOS3 in stem cell mobilization. Trends Mol. Med. 10 (2004) 421-425
7. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwaoto M.A., Park J.E., Nguyen H.V., Aiello L.M., Ferrara N., and King G.L. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331 (1994) 1480-1487
8. Aiuti A., Webb I.J., Bleul C., Springer T., and Gutierrez-Ramos J.C. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J. Exp. Med. 185 (1997) 111-120
9. Asahara T., Murohara T., Sullivan A., Silver M., van der Zee R., and Li T. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275 (1997) 964-967
10. Autiero M., Luttun A., Tjwa M., and Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J. Thromb. Haemost. 1 (2003) 1356-1370
11. Autiero M., Waltenberger J., Communi D., Kranz A., Moons L., Lambrechts D., Kroll J., Plaisance S., De Mol M., Bono F., Kliche S., Fellbrich G., Ballmer-Hofer K., Maglione D., Mayr-Beyrle U., Dewerchin M., Dombrowski S., Stanimirovic D., Van Hummelen P., Dehio C., Hicklin D.J., Persico G., Herbert J.M., Shibuya M., Collen D., Conway E.M., and Carmeliet P. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat. Med. 9 (2003) 936-943
12. Averbukh E., Weiss O., Halpert M., Yanko R., Moshe R., Nephesh I., Flyvbjerg A., Yanko L., and Raz I. Gene expression of insulin-like growth factor-I, its receptor and binding proteins in retina under hypoxic conditions. Metabolism 47 (1998) 1331-1336
13. Avery R.L., Pearlman J., Pieramici D.J., Rabena M.D., Castellarin A.A., Nasir M.A., Giust M.J., Wendel R., and Patel A. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113 1695 (2006) e1615-e1691
14. Bahlmann F.H., De Groot K., Spandau J.M., Landry A.L., Hertel B., Duckert T., Boehm S.M., Menne J., Haller H., and Fliser D. Erythropoietin regulates endothelial progenitor cells. Blood 103 (2004) 921-926
15. Banin E., Dorrell M.I., Aguilar E., Ritter M.R., Aderman C.M., Smith A.C., Friedlander J., and Friedlander M. T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification. Invest Ophthalmol. Visual Sci. 47 (2006) 2125-2134
16. Bicknell R., and Harris A.L. Novel angiogenic signaling pathways and vascular targets. Annu. Rev. Pharmacol. Toxicol. 44 (2004) 219-238
17. Bilton R.L., and Booker G.W. The subtle side to hypoxia inducible factor (HIFalpha) regulation. Eur. J. Biochem. 270 (2003) 791-798
18. Bouck N. PEDF: anti-angiogenic guardian of ocular function. Trends Mol. Med. 8 (2002) 330-334
19. Brasier A.R. The NF-kappaB regulatory network. Cardiovasc. Toxicol. 6 (2006) 111-130
20. Brooks Jr. H.L., Caballero Jr. S., Newell C.K., Steinmetz R.L., Watson D., Segal M.S., Harrison J.K., Scott E.W., and Grant M.B. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Arch. Ophthalmol. 122 (2004) 1801-1807
21. Brown M.M., Brown G.C., Stein J.D., Roth Z., Campanella J., and Beauchamp G.R. Age-related macular degeneration: economic burden and value-based medicine analysis. Can. J. Ophthalmol. 40 (2005) 277-287
22. Brown D.M., Kaiser P.K., Michels M., Soubrane G., Heier J.S., Kim R.Y., Sy J.P., and Schneider S. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355 (2006) 1432-1444
23. Brugger W., Heimfeld S., Berenson R.J., Mertelsmann R., and Kanz L. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N. Engl. J. Med. 333 (1995) 283-287
24. Brunkan A.L., and Goate A.M. Presenilin function and gamma-secretase activity. J. Neurochem. 93 (2005) 769-792
25. Burkhardt C., and Zacharias M. Modelling ion binding to AA platform motifs in RNA: a continuum solvent study including conformational adaptation. Nucleic Acids Res. 29 (2001) 3910-3918
26. Caballero S., Sengupta N., Afzal A., Chang K.H., Li Calzi S., Guberski D.L., Kern T.S., and Grant M.B. Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes 56 (2007) 960-967
27. Cai J., Jiang W.G., Ahmed A., and Boulton M. Vascular endothelial growth factor-induced endothelial cell proliferation is regulated by interaction between VEGFR-2, SH-PTP1 and eNOS. Microvasc. Res. 71 (2006) 20-31
28. Cai J., Jiang W.G., Grant M.B., and Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J. Biol. Chem. 281 (2006) 3604-3613
29. Castellon R., Caballero S., Hamdi H.K., Atilano S.R., Aoki A.M., Tarnuzzer R.W., Kenney M.C., Grant M.B., and Ljubimov A.V. Effects of tenascin-C on normal and diabetic retinal endothelial cells in culture. Invest Ophthalmol. Visual Sci. 43 (2002) 2758-2766
30. Clauss M., Weich H., Breier G., Knies U., Rockl W., Waltenberger J., and Risau W. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem. 271 (1996) 17629-17634
31. Coussens L.M., Raymond W.W., Bergers G., Laig-Webster M., Behrendtsen O., Werb Z., Caughey G.H., and Hanahan D. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13 (1999) 1382-1397
32. Crosby J.R., Kaminski W.E., Schatteman G., Martin P.J., Raines E.W., Seifert R.A., and Bowen-Pope D.F. Endothelial cells of hematopoietic origin make a significant contribution to adult blood vessel formation. Circ. Res. 87 (2000) 728-730
33. Cunningham Jr. E.T., Adamis A.P., Altaweel M., Aiello L.P., Bressler N.M., D'Amico D.J., Goldbaum M., Guyer D.R., Katz B., Patel M., and Schwartz S.D. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112 (2005) 1747-1757
34. Cursiefen C., Chen L., Borges L.P., Jackson D., Cao J., Radziejewski C., D'Amore P.A., Dana M.R., Wiegand S.J., and Streilein J.W. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest. 113 (2004) 1040-1050
35. Dawson D.W., Volpert O.V., Gillis P., Crawford S.E., Xu H., Benedict W., and Bouck N.P. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285 (1999) 245-248
36. Delafontaine P., Song Y.H., and Li Y. Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 435-444
37. Dewan A., Liu M., Hartman S., Zhang S.S., Liu D.T., Zhao C., Tam P.O., Chan W.M., Lam D.S., Snyder M., Barnstable C., Pang C.P., and Hoh J. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 314 (2006) 989-992
38. Dimmeler S., Aicher A., Vasa M., Mildner-Rihm C., Adler K., Tiemann M., Rutten H., Fichtlscherer S., Martin H., and Zeiher A.M. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 108 (2001) 391-397
39. Dimmeler S., Aicher A., Vasa M., Mildner-Rihm C., Adler K., Tiemann M., Rutten H., Fichtlscherer S., Martin H., and Zeiher A.M. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J. Clin. Invest. 108 (2001) 391-397
40. Donoso L.A., Kim D., Frost A., Callahan A., and Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol. 51 (2006) 137-152
41. Dorrell M.I., Aguilar E., Scheppke L., Barnett F.H., and Friedlander M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 967-972
42. Dorrell M., Uusitalo-Jarvinen H., Aguilar E., and Friedlander M. Ocular neovascularization: basic mechanisms and therapeutic advances. Surv. Ophthalmol. 52 Suppl. 1 (2007) S3-S19
43. Economopoulou M., Bdeir K., Cines D.B., Fogt F., Bdeir Y., Lubkowski J., Lu W., Preissner K.T., Hammes H.P., and Chavakis T. Inhibition of pathologic retinal neovascularization by alpha-defensins. Blood 106 (2005) 3831-3838
44. Feindt J., Becker I., Blomer U., Hugo H.H., Mehdorn H.M., Krisch B., and Mentlein R. Expression of somatostatin receptor subtypes in cultured astrocytes and gliomas. J. Neurochem. 65 (1995) 1997-2005
45. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 (2004) 2-10
46. Firth S.M., McDougall F., McLachlan A.J., and Baxter R.C. Impaired blockade of insulin-like growth factor I (IGF-I)-induced hypoglycemia by IGF binding protein-3 analog with reduced ternary complex-forming ability. Endocrinology 143 (2002) 1669-1676
47. Flamme I., and Risau W. Induction of vasculogenesis and hematopoiesis in vitro. Development 116 (1992) 435-439
48. Fong Y., Federoff H.J., Brownlee M., Blumberg D., Blumgart L.H., and Brennan M.F. Rapid and efficient gene transfer in human hepatocytes by herpes viral vectors. Hepatology 22 (1995) 723-729
49. Friedlander M., Theesfeld C.L., Sugita M., Fruttiger M., Thomas M.A., Chang S., and Cheresh D.A. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 9764-9769
50. Friedlander M., Dorrell M.I., Ritter M.R., Marchetti V., Moreno S.K., El-Kalay M., Bird A.C., Banin E., and Aguilar E. Progenitor cells and retinal angiogenesis. Angiogenesis 10 (2007) 89-101
51. Friedman D.S., O'Colmain B.J., Munoz B., Tomany S.C., McCarty C., de Jong P.T., Nemesure B., Mitchell P., and Kempen J. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122 (2004) 564-572
52. Garber K. New drugs target hypoxia response in tumors. J. Natl. Cancer Inst. 97 (2005) 1112-1114
53. Geissmann F., Jung S., and Littman D.R. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19 (2003) 71-82
54. George J., Goldstein E., Abashidze A., Wexler D., Hamed S., Shmilovich H., Deutsch V., Miller H., Keren G., and Roth A. Erythropoietin promotes endothelial progenitor cell proliferative and adhesive properties in a PI 3-kinase-dependent manner. Cardiovasc. Res. 68 (2005) 299-306
55. Granata R., Trovato L., Garbarino G., Taliano M., Ponti R., Sala G., Ghidoni R., and Ghigo E. Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J. 18 (2004) 1456-1458
56. Grant M.B. Insulinlike growth factor-I in diabetic vascular complications. Curr. Opin. Endocrinol. Diabetes 3 (1996) 335-345
57. Grant M.B., Russell B., Fitzgerald C., and Merimee T.J. Insulin-like growth factors in vitreous: studies in control and diabetic subjects with neovascularization. Diabetes 35 (1986) 416-420
58. Grant M.B., Schmetz I., Russell B., Harwood H., Silverstein J., and Merimee T.J. Changes in insulin-like growth factors I and II and their binding protein after a single intramuscular injection of growth hormone. J. Clin. Endocrinol. Metab. 63 (1986) 981-984
59. Grant M.B., Mames R.N., Fitzgerald C., Ellis E.A., Caballero S., Chegini N., and Guy J. Insulin-like growth factor I as an angiogenic agent. In vivo and in vitro studies. Ann. N. Y. Acad. Sci. 692 (1993) 230-242
60. Grant M.B., Caballero S., Bush D.M., and Spoerri P.E. Fibronectin fragments modulate human retinal capillary cell proliferation and migration. Diabetes 47 (1998) 1335-1340
61. Grant M.B., Caballero S., Tarnuzzer R.W., Bass K.E., Ljubimov A.V., Spoerri P.E., and Galardy R.E. Matrix metalloproteinase expression in human retinal microvascular cells. Diabetes 47 (1998) 1311-1317
62. Grant M.B., Chang K.H., Afzal A., Li Calzi S., Pan H., Shaw L.C., Baxter L., McFarland E., Chan-Ling T., and Sullivan S.M. Insulin-like Growth Factor Binding Protein-3 (IGFBP-3) Regulates Endothelial Precursor Cells (EPC) Differentiation in vitro and in vivo. ENDO2006 (2006), Annual Meeting of the Endocrinology Society, Toronto, Canada
63. Gu Z., Kaul M., Yan B., Kridel S.J., Cui J., Strongin A., Smith J.W., Liddington R.C., and Lipton S.A. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297 (2002) 1186-1190
64. Habtemariam T., Yu P., Oryang D., Nganwa D., Ayanwale O., Tameru B., Abdelrahman H., Ahmad A., and Robnett V. Modelling viral and CD4 cellular population dynamics in HIV: approaches to evaluate intervention strategies. Cell. Mol. Biol. (Noisy-le-grand) 47 (2001) 1201-1208
65. Haskell M.D., Slack J.K., Parsons J.T., and Parsons S.J. c-Src tyrosine phosphorylation of epidermal growth factor receptor, P190 RhoGAP, and focal adhesion kinase regulates diverse cellular processes. Chem. Rev. 101 (2001) 2425-2440
66. Hattori K., Heissig B., and Rafii S. The regulation of hematopoietic stem cell and progenitor mobilization by chemokine SDF-1. Leuk. Lymphoma 44 (2003) 575-582
67. Heeschen C., Weis M., Aicher A., Dimmeler S., and Cooke J.P. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J. Clin. Invest. 110 (2002) 527-536
68. Heeschen C., Chang E., Aicher A., and Cooke J.P. Endothelial progenitor cells participate in nicotine-mediated angiogenesis. J. Am. Coll. Cardiol. 48 (2006) 2553-2560
69. Heissig B., Hattori K., Dias S., Friedrich M., Ferris B., Hackett N.R., Crystal R.G., Besmer P., Lyden D., Moore M.A., Werb Z., and Rafii S. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109 (2002) 625-637
70. Hellstrom A., Engstrom E., Hard A.L., Albertsson-Wikland K., Carlsson B., Niklasson A., Lofqvist C., Svensson E., Holm S., Ewald U., Holmstrom G., and Smith L.E. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 112 (2003) 1016-1020
71. Hellstrom M., Phng L.K., Hofmann J.J., Wallgard E., Coultas L., Lindblom P., Alva J., Nilsson A.K., Karlsson L., Gaiano N., Yoon K., Rossant J., Iruela-Arispe M.L., Kalen M., Gerhardt H., and Betsholtz C. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445 (2007) 776-780
72. Hill J.M., Zalos G., Halcox J.P., Schenke W.H., Waclawiw M.A., Quyyumi A.A., and Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N. Engl. J. Med. 348 (2003) 593-600
73. Hiratsuka S., Minowa O., Kuno J., Noda T., and Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 9349-9354
74. Hiratsuka S., Nakamura K., Iwai S., Murakami M., Itoh T., Kijima H., Shipley J.M., Senior R.M., and Shibuya M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2 (2002) 289-300
75. Hubert A., Paris S., Piret J.P., Ninane N., Raes M., and Michiels C. Casein kinase 2 inhibition decreases hypoxia-inducible factor-1 activity under hypoxia through elevated p53 protein level. J. Cell Sci. 119 (2006) 3351-3362
76. Hyer S.L. Growth hormone suppression in diabetic retinopathy. Diabetologia 30 (1987) 534A
77. Iwakura A., Luedemann C., Shastry S., Hanley A., Kearney M., Aikawa R., Isner J.M., Asahara T., and Losordo D.W. Estrogen-mediated, endothelial nitric oxide synthase-dependent mobilization of bone marrow-derived endothelial progenitor cells contributes to reendothelialization after arterial injury. Circulation 108 (2003) 3115-3121
78. Jiang S., Walker L., Afentoulis M., Anderson D.A., Jauron-Mills L., Corless C.L., and Fleming W.H. Transplanted human bone marrow contributes to vascular endothelium. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 16891-16896
79. Jo N., Mailhos C., Ju M., Cheung E., Bradley J., Nishijima K., Robinson G.S., Adamis A.P., and Shima D.T. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am. J. Pathol. 168 (2006) 2036-2053
80. Johnson T.S., Haylor J.L., Thomas G.L., Fisher M., and El Nahas A.M. Matrix metalloproteinases and their inhibitions in experimental renal scarring. Exp. Nephrol. 10 (2002) 182-195
81. Klisovic D.D., O'Dorisio M.S., Katz S.E., Sall J.W., Balster D., O'Dorisio T.M., Craig E., and Lubow M. Somatostatin receptor gene expression in human ocular tissues: RT-PCR and immunohistochemical study. Invest Ophthalmol. Visual Sci. 42 (2001) 2193-2201
82. Kocher A.A., Schuster M.D., Szabolcs M.J., Takuma S., Burkhoff D., Wang J., Homma S., Edwards N.M., and Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7 (2001) 430-436
83. Kramerov A.A., Saghizadeh M., Pan H., Kabosova A., Montenarh M., Ahmed K., Penn J.S., Chan C.K., Hinton D.R., Grant M.B., and Ljubimov A.V. Expression of protein kinase CK2 in astroglial cells of normal and neovascularized retina. Am. J. Pathol. 168 (2006) 1722-1736
84. Kremer C., Breier G., Risau W., and Plate K.H. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res. 57 (1997) 3852-3859
85. Kumar U. Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: an immunohistochemical analysis. Neuroscience 134 (2005) 525-538
86. Lagaaij E.L., Cramer-Knijnenburg G.F., van Kemenade F.J., van Es L.A., Bruijn J.A., and van Krieken J.H. Endothelial cell chimerism after renal transplantation and vascular rejection. Lancet 357 (2001) 33-37
87. Lanzkron S.M., Collector M.I., and Sharkis S.J. Hematopoietic stem cell tracking in vivo: a comparison of short-term and long-term repopulating cells. Blood 93 (1999) 1916-1921
88. Litchfield D.W. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem. J. 369 (2003) 1-15
89. Liu B., Lee K.W., Li H., Ma L., Lin G.L., Chandraratna R.A., and Cohen P. Combination therapy of insulin-like growth factor binding protein-3 and retinoid X receptor ligands synergize on prostate cancer cell apoptosis in vitro and in vivo. Clin. Cancer Res. 11 (2005) 4851-4856
90. Ljubimov A.V., Burgeson R.E., butkowski R.J., Couchman J.R., Zardi L., Ninomiya Y., Sado Y., Huang Z.S., Nesburn A.B., and Kenney M.C. Basement membrane abnormalities in human eyes with diabetic retinopathy. J. Histochem. Cytochem. 44 (1996) 1469-1479
91. Ljubimov A.V., Caballero S., Aoki A.M., Pinna L.A., Grant M.B., and Castellon R. Involvement of protein kinase CK2 in angiogenesis and retinal neovascularization. Invest Ophthalmol. Visual Sci. 45 (2004) 4583-4591
92. Ljubimova J.Y., Fujita M., Khazenzon N.M., Lee B.S., Wachsmann-Hogiu S., Farkas D.L., Black K.L., and Holler E. Nanoconjugate based on polymalic acid for tumor targeting. Chem.-Biol. Interact. 168 (2007) (Epub ahead of print)
93. Llevadot J., Murasawa S., Kureishi Y., Uchida S., Masuda H., Kawamoto A., Walsh K., Isner J.M., and Asahara T. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J. Clin. Invest. 108 (2001) 399-405
94. Lofqvist C., Engstrom E., Sigurdsson J., Hard A.L., Niklasson A., Ewald U., Holmstrom G., Smith L.E., and Hellstrom A. Postnatal head growth deficit among premature infants parallels retinopathy of prematurity and insulin-like growth factor-1 deficit. Pediatrics 117 (2006) 1930-1938
95. Lukiw W.J., Gordon W.C., Rogaev E.I., Thompson H., and Bazan N.G. Presenilin-2 (PS2) expression up-regulation in a model of retinopathy of prematurity and pathoangiogenesis. NeuroReport 12 (2001) 53-57
96. Luttun A., Tjwa M., Moons L., Wu Y., Angelillo-Scherrer A., Liao F., Nagy J.A., Hooper A., Priller J., De Klerck B., Compernolle V., Daci E., Bohlen P., Dewerchin M., Herbert J.M., Fava R., Matthys P., Carmeliet G., Collen D., Dvorak H.F., Hicklin D.J., and Carmeliet P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med. 8 (2002) 831-840
97. Malecaze F., Clamens S., Simorre-Pinatel V., Mathis A., Chollet P., Favard C., Bayard F., and Plouet J. Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch. Ophthalmol. 112 (1994) 1476-1482
98. Merimee T.J., Zapf J., and Froesch E.R. Insulin-like growth factors: studies in diabetics with and without retinopathy. N. Engl. J. Med. 309 (1983) 527-530
99. Meyer M., Clauss M., Lepple-Wienhues A., Waltenberger J., Augustin H.G., Ziche M., Lanz C., Buttner M., Rziha H.J., and Dehio C. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J. 18 (1999) 363-374
100. Moldovan N.I., Goldschmidt-Clermont P.J., Parker-Thornburg J., Shapiro S.D., and Kolattukudy P.E. Contribution of monocytes/macrophages to compensatory neovascularization: the drilling of metalloelastase-positive tunnels in ischemic myocardium. Circ. Res. 87 (2000) 378-384
101. Moralez A., Busby Jr. W.H., and Clemmons D. Control of insulin-like growth factor binding protein-5 protease synthesis and secretion by human fibroblasts and porcine aortic smooth muscle cells. Endocrinology 144 (2003) 2489-2495
102. Murakami Y., Yamagoe S., Noguchi K., Takebe Y., Takahashi N., Uehara Y., and Fukazawa H. Ets-1-dependent expression of vascular endothelial growth factor receptors is activated by latency-associated nuclear antigen of Kaposi's Sarcoma-associated herpesvirus through interaction with daxx. J. Biol. Chem. 281 (2006) 28113-28121
103. Murohara T., Horowitz J.R., Silver M., Tsurumi Y., Chen D., Sullivan A., and Isner J.M. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 97 (1998) 99-107
104. Nakajima M., Yuasa S., Ueno M., Takakura N., Koseki H., and Shirasawa T. Abnormal blood vessel development in mice lacking presenilin-1. Mech. Dev. 120 (2003) 657-667
105. Nakajima M., Ogawa M., Shimoda Y., Hiraoka S., Iida M., Koseki H., Shirasawa T., and Furukawa K. Presenilin-1 controls the growth and differentiation of endothelial progenitor cells through its beta-catenin-binding region. Cell Biol. Int. 30 (2006) 239-243
106. Nakamura M., Kawahara M., Nakata K., and Nishida T. Restoration of corneal epithelial barrier function and wound healing by substance P and IGF-1 in rats with capsaicin-induced neurotrophic keratopathy. Invest. Ophthalmol. Visual Sci. 44 (2003) 2937-2940
107. Neu J., Afzal A., Pan H., Gallego E., Li N., Li Calzi S., Caballero S., Spoerri P.E., Shaw L.C., and Grant M.B. The dipeptide Arg-Gln inhibits retinal neovascularization in the mouse model of oxygen-induced retinopathy. Invest. Ophthalmol. Visual Sci. 47 (2006) 3151-3155
108. Noguera-Troise I., Daly C., Papadopoulos N.J., Coetzee S., Boland P., Gale N.W., Lin H.C., Yancopoulos G.D., and Thurston G. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 444 (2006) 1032-1037
109. Nozaki M., Sakurai E., Raisler B.J., Baffi J.Z., Witta J., Ogura Y., Brekken R.A., Sage E.H., Ambati B.K., and Ambati J. Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. J. Clin. Invest. 116 (2006) 422-429
110. Nozaki M., Raisler B.J., Sakurai E., Sarma J.V., Barnum S.R., Lambris J.D., Chen Y., Zhang K., Ambati B.K., Baffi J.Z., and Ambati J. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 2328-2333
111. Ogawa S., Oku A., Sawano A., Yamaguchi S., Yazaki Y., and Shibuya M. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 273 (1998) 31273-31282
112. Ogata N., Wada M., Otsuji T., Jo N., Tombran-Tink J., and Matsumura M. Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. Invest. Ophthalmol. Visual Sci. 43 (2002) 1168-1175
113. Pagano M.A., Cesaro L., Meggio F., and Pinna L.A. Protein kinase CK2: a newcomer in the 'druggable kinome'. Biochem. Soc. Trans. 34 (2006) 1303-1306
114. Palii S.S., Caballero Jr. S., Shapiro G., and Grant M.B. Medical treatment of diabetic retinopathy with somatostatin analogues. Expert Opin. Investig. Drugs 16 (2007) 73-82
115. Patel Y.C. Somatostatin and its receptor family. Front. Neuroendocrinol. 20 (1999) 157-198
116. Patel N.S., Li J.L., Generali D., Poulsom R., Cranston D.W., and Harris A.L. Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res. 65 (2005) 8690-8697
117. Peichev M., Naiyer A.J., Pereira D., Zhu Z., Lane W.J., Williams M., Oz M.C., Hicklin D.J., Witte L., Moore M.A., and Rafii S. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95 (2000) 952-958
118. Peters B.A., Diaz L.A., Polyak K., Meszler L., Romans K., Guinan E.C., Antin J.H., Myerson D., Hamilton S.R., Vogelstein B., Kinzler K.W., and Lengauer C. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat. Med. 11 (2005) 261-262
119. Pipp F., Heil M., Issbrucker K., Ziegelhoeffer T., Martin S., van den Heuvel J., Weich H., Fernandez B., Golomb G., Carmeliet P., Schaper W., and Clauss M. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ. Res. 92 (2003) 378-385
120. Poole A., Poore T., Bandhakavi S., McCann R.O., Hanna D.E., and Glover C.V. A global view of CK2 function and regulation. Mol. Cell. Biochem. 274 (2005) 163-170
121. Poulsen J.E. Recovery from retinopathy in a case of diabetes with Simmonds' disease. Diabetes 2 (1953) 7-12
122. Quaini F., Urbanek K., Beltrami A.P., Finato N., Beltrami C.A., Nadal-Ginard B., Kajstura J., Leri A., and Anversa P. Chimerism of the transplanted heart. N. Engl. J. Med. 346 (2002) 5-15
123. Quirici N., Soligo D., Caneva L., Servida F., Bossolasco P., and Deliliers G.L. Differentiation and expansion of endothelial cells from human bone marrow CD133(+) cells. Br. J. Haematol. 115 (2001) 186-194
124. Rafii S., Meeus S., Dias S., Hattori K., Heissig B., Shmelkov S., Rafii D., and Lyden D. Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin. Cell Dev. Biol. 13 (2002) 61-67
125. Rahimi N. VEGFR-1 and VEGFR-2: two non-identical twins with a unique physiognomy. Front. Biosci. 11 (2006) 818-829
126. Rahimi N., Dayanir V., and Lashkari K. Receptor chimeras indicate that the vascular endothelial growth factor receptor-1 (VEGFR-1) modulates mitogenic activity of VEGFR-2 in endothelial cells. J. Biol. Chem. 275 (2000) 16986-16992
127. Reich S.J., Fosnot J., Kuroki A., Tang W., Yang X., Maguire A.M., Bennett J., and Tolentino M.J. Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9 (2003) 210-216
128. Rich R.M., Rosenfeld P.J., Puliafito C.A., Dubovy S.R., Davis J.L., Flynn Jr. H.W., Gonzalez S., Feuer W.J., Lin R.C., Lalwani G.A., Nguyen J.K., and Kumar G. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26 (2006) 495-511
129. Ridgway J., Zhang G., Wu Y., Stawicki S., Liang W.C., Chanthery Y., Kowalski J., Watts R.J., Callahan C., Kasman I., Singh M., Chien M., Tan C., Hongo J.A., de Sauvage F., Plowman G., and Yan M. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 444 (2006) 1083-1087
130. Riecke B., Chavakis E., Bretzel R.G., Linn T., Preissner K.T., Brownlee M., and Hammes H.P. Topical application of integrin antagonists inhibits proliferative retinopathy. Horm. Metab. Res. 33 (2001) 307-311
131. Roberts D.M., Kearney J.B., Johnson J.H., Rosenberg M.P., Kumar R., and Bautch V.L. The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am. J. Pathol. 164 (2004) 1531-1535
132. Rosenfeld P.J., Fung A.E., and Puliafito C.A. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg. Lasers Imaging 36 (2005) 336-339
133. Rosenfeld P.J., Rich R.M., and Lalwani G.A. Ranibizumab: phase III clinical trial results. Ophthalmol. Clin. North Am. 19 (2006) 361-372
134. Sainson R.C., Aoto J., Nakatsu M.N., Holderfield M., Conn E., Koller E., and Hughes C.C. Cell-autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis. FASEB J. 19 (2005) 1027-1029
135. Sakai K., Busby W.H., Clarke J.B., and Clemmons D.R. Tissue transglutaminase facilitates the polymerization of insulin-like growth factor-binding protein-1 (IGFBP-1) and leads to loss of IGFBP-1's ability to inhibit insulin-like growth factor-I-stimulated protein synthesis. J. Biol. Chem. 276 (2001) 8740-8745
136. Sawano A., Iwai S., Sakurai Y., Ito M., Shitara K., Nakahata T., and Shibuya M. Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood 97 (2001) 785-791
137. Schatteman G.C., and Awad O. Hemangioblasts, angioblasts, and adult endothelial cell progenitors. Anat. Rec. A Discov. Mol. Cell Evol. Biol. 276 (2004) 13-21
138. Schatteman G.C., and Ma N. Old bone marrow cells inhibit skin wound vascularization. Stem Cells 24 (2006) 717-721
139. Schatteman G.C., Hanlon H.D., Jiao C., Dodds S.G., and Christy B.A. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J. Clin. Invest. 106 (2000) 571-578
140. Schmidt-Lucke C., Rossig L., Fichtlscherer S., Vasa M., Britten M., Kamper U., Dimmeler S., and Zeiher A.M. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 111 (2005) 2981-2987
141. Semenza G.L. HIF-1: using two hands to flip the angiogenic switch. Cancer Metastasis Rev. 19 (2000) 59-65
142. Sen K., Misra A., Kumar A., and Pandey R.M. Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia. Diabetes Res. Clin. Pract. 56 (2002) 1-11
143. Sengupta N., Caballero S., Mames R.N., Timmers A.M., Saban D., and Grant M.B. Preventing stem cell incorporation into choroidal neovascularization by targeting homing and attachment factors. Invest Ophthalmol. Visual Sci. 46 (2005) 343-348
144. Serneels L., Dejaegere T., Craessaerts K., Horre K., Jorissen E., Tousseyn T., Hebert S., Coolen M., Martens G., Zwijsen A., Annaert W., Hartmann D., and De Strooper B. Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 1719-1724
145. Shi W., and Harris A.L. Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J. Mammary Gland Biol. Neoplasia 11 (2006) 41-52
146. Shi Q., Rafii S., Wu M.-D., Wijelath E., Yu C., Ishida A., Fujita Y., Kothari S., Mohle R., Sauvage L., Malcom A., Storb R., and Hammond W. Evidence for circulating bone marrow-derived endothelial cells. Blood 92 (1998) 362-367
147. Sivan-Loukianova E., Awad O.A., Stepanovic V., Bickenbach J., and Schatteman G.C. CD34+ blood cells accelerate vascularization and healing of diabetic mouse skin wounds. J. Vasc. Res. 40 (2003) 368-377
148. Smith L.E., Shen W., Perruzzi C., Soker S., Kinose F., Xu X., Robinson G., Driver S., Bischoff J., Zhang B., Schaeffer J.M., and Senger D.R. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat. Med. 5 (1999) 1390-1395
149. Spaide R.F., and Fisher Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26 (2006) 275-278
150. Spaide R.F., Laud K., Fine H.F., Klancnik Jr. J.M., Meyerle C.B., Yannuzzi L.A., Sorenson J., Slakter J., Fisher Y.L., and Cooney M.J. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26 (2006) 383-390
151. Spraul C.W., Baldysiak-Figiel A., Lang G.K., and Lang G.E. Octreotide inhibits growth factor-induced bovine choriocapillary endothelial cells in vitro. Graefe's Arch. Clin. Exp. Ophthalmol. 240 (2002) 227-231
152. Steeghs N., Nortier J.W., and Gelderblom H. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments. Ann. Surg. Oncol. 14 (2007) 942-953
153. Stellmach V.V., Crawford S.E., Zhou W., and Bouck N. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2593-2597
154. Sterescu A.E., Rousseau-Harsany E., Farrell C., Powell J., David M., and Dubois J. The potential efficacy of omega-3 fatty acids as anti-angiogenic agents in benign vascular tumors of infancy. Med. Hypotheses 66 (2006) 1121-1124
155. Strehlow K., Werner N., Berweiler J., Link A., Dirnagl U., Priller J., Laufs K., Ghaeni L., Milosevic M., Bohm M., and Nickenig G. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 107 (2003) 3059-3065
156. Tombran-Tink J., Lara N., Chappa A., Tink A.R., Johnson L.V., and Staples M. Identification of downstream mechanisms involved in PEDF'S activity in the retina by large scale gene expression profiling. Adv. Exp. Med. Biol. 533 (2003) 315-326
157. Tonnesen M.G., Feng X., and Clark R.A. Angiogenesis in wound healing. J. Investig. Dermatol. Symp. Proc. 5 (2000) 40-46
158. Vasilaki A., Papadaki T., Notas G., Kolios G., Mastrodimou N., Hoyer D., Tsilimbaris M., Kouroumalis E., Pallikaris I., and Thermos K. Effect of somatostatin on nitric oxide production in human retinal pigment epithelium cell cultures. Invest Ophthalmol. Visual Sci. 45 (2004) 1499-1506
159. Walter D.H., and Dimmeler S. Endothelial progenitor cells: regulation and contribution to adult neovascularization. Herz 27 (2002) 579-588
160. Watanabe D., Takagi H., Suzuma K., Oh H., Ohashi H., and Honda Y. Expression of connective tissue growth factor and its potential role in choroidal neovascularization. Retina 25 (2005) 911-918
161. Weiss M., Gross-Weege W., Harms B., and Schneider E.M. Filgrastim (RHG-CSF) related modulation of the inflammatory response in patients at risk of sepsis or with sepsis. Cytokine 8 (1996) 260-265
162. Wilkinson-Berka J.L., Wraight C., and Werther G. The role of growth hormone, insulin-like growth factor and somatostatin in diabetic retinopathy. Curr. Med. Chem. 13 (2006) 3307-3317
163. Williams C.K., Li J.L., Murga M., Harris A.L., and Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 107 (2006) 931-939
164. Wilson S.H., Davis M.I., Caballero S., and Grant M.B. Modulation of retinal endothelial cell behavior by somatostatin analogues: implications for diabetic retinopathy. Growth Hormone and IGF Research. Monte Carlo, Monaco: Oxford Clinical Communications (2001)
165. Witmer A.N., Vrensen G.F., Van Noorden C.J., and Schlingemann R.O. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retinal Eye Res. 22 (2003) 1-29
166. Wolfe M.S. The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 45 (2006) 7931-7939
167. Yamagishi S., Nakamura K., Matsui T., Sato T., and Takeuchi M. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy. Med. Hypotheses 66 (2006) 1019-1021
168. Yamaguchi A., Ikeda Y., Hirai T., Fujikawa T., and Morita I. Local changes of IGF-I mRNA, GH receptor mRNA, and fiber size in rat plantaris muscle following compensatory overload. Jpn. J. Physiol. 53 (2003) 53-60
169. Yang Z., Camp N.J., Sun H., Tong Z., Gibbs D., Cameron D.J., Chen H., Zhao Y., Pearson E., Li X., Chien J., Dewan A., Harmon J., Bernstein P.S., Shridhar V., Zabriskie N.A., Hoh J., Howes K., and Zhang K. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 314 (2006) 992-993
170. Zeng H., Dvorak H.F., and Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) preceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J. Biol. Chem. 276 (2001) 26969-26979
171. Ziche M., Maglione D., Ribatti D., Morbidelli L., Lago C.T., Battisti M., Paoletti I., Barra A., Tucci M., Parise G., Vincenti V., Granger H.J., Viglietto G., and Persico M.G. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab. Invest. 76 (1997) 517-531